Peroxisome Proliferator-Activated Receptors Associated with Nonalcoholic Fatty Liver Disease
Nonalcoholic fatty liver disease (NAFLD) is rapidly becoming a major cause of chronic liver disease worldwide. Concurrent to an increase in NAFLD prevalence, there is an increase in the obesity epidemic and the correlated insulin-resistant state. It is a challenge to diagnose NAFLD because many pati...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Hindawi Limited
2017-01-01
|
| Series: | PPAR Research |
| Online Access: | http://dx.doi.org/10.1155/2017/6561701 |
| _version_ | 1798044014747844608 |
|---|---|
| author | Nan Wang Rui Kong Hui Luo Xiaorong Xu Jie Lu |
| author_facet | Nan Wang Rui Kong Hui Luo Xiaorong Xu Jie Lu |
| author_sort | Nan Wang |
| collection | DOAJ |
| description | Nonalcoholic fatty liver disease (NAFLD) is rapidly becoming a major cause of chronic liver disease worldwide. Concurrent to an increase in NAFLD prevalence, there is an increase in the obesity epidemic and the correlated insulin-resistant state. It is a challenge to diagnose NAFLD because many patients are asymptomatic until the later stages of disease. The most common symptoms include fatigue, malaise, and discomfort in the right upper quadrant. The major and most accurate tool to clinically diagnose NAFLD is a liver biopsy, followed by histological analysis. However, this procedure is invasive and often carries a high risk of complications. Currently, there are no officially approved medications for the treatment of NAFLD. Although lifestyle modifications with proper diet and exercise have been shown to be beneficial, this has been difficult to achieve and sustain for many patients. Effective pharmacological treatments are still lacking; therefore, additional research to identify novel drugs is clearly warranted. PPARs are promising drug targets for the management of NAFLD and its related conditions of type 2 diabetes mellitus and cardiovascular disease. In this review, we provide an overview of recent studies on the association of PPARs and NAFLD. |
| first_indexed | 2024-04-11T22:57:02Z |
| format | Article |
| id | doaj.art-12c0ca006a774b23b4dcf6bb8cf6dddb |
| institution | Directory Open Access Journal |
| issn | 1687-4757 1687-4765 |
| language | English |
| last_indexed | 2024-04-11T22:57:02Z |
| publishDate | 2017-01-01 |
| publisher | Hindawi Limited |
| record_format | Article |
| series | PPAR Research |
| spelling | doaj.art-12c0ca006a774b23b4dcf6bb8cf6dddb2022-12-22T03:58:20ZengHindawi LimitedPPAR Research1687-47571687-47652017-01-01201710.1155/2017/65617016561701Peroxisome Proliferator-Activated Receptors Associated with Nonalcoholic Fatty Liver DiseaseNan Wang0Rui Kong1Hui Luo2Xiaorong Xu3Jie Lu4Department of Gastroenterology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai 200072, ChinaDepartment of Gastroenterology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai 200072, ChinaDepartment of Gastroenterology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai 200072, ChinaDepartment of Gastroenterology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai 200072, ChinaDepartment of Gastroenterology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai 200072, ChinaNonalcoholic fatty liver disease (NAFLD) is rapidly becoming a major cause of chronic liver disease worldwide. Concurrent to an increase in NAFLD prevalence, there is an increase in the obesity epidemic and the correlated insulin-resistant state. It is a challenge to diagnose NAFLD because many patients are asymptomatic until the later stages of disease. The most common symptoms include fatigue, malaise, and discomfort in the right upper quadrant. The major and most accurate tool to clinically diagnose NAFLD is a liver biopsy, followed by histological analysis. However, this procedure is invasive and often carries a high risk of complications. Currently, there are no officially approved medications for the treatment of NAFLD. Although lifestyle modifications with proper diet and exercise have been shown to be beneficial, this has been difficult to achieve and sustain for many patients. Effective pharmacological treatments are still lacking; therefore, additional research to identify novel drugs is clearly warranted. PPARs are promising drug targets for the management of NAFLD and its related conditions of type 2 diabetes mellitus and cardiovascular disease. In this review, we provide an overview of recent studies on the association of PPARs and NAFLD.http://dx.doi.org/10.1155/2017/6561701 |
| spellingShingle | Nan Wang Rui Kong Hui Luo Xiaorong Xu Jie Lu Peroxisome Proliferator-Activated Receptors Associated with Nonalcoholic Fatty Liver Disease PPAR Research |
| title | Peroxisome Proliferator-Activated Receptors Associated with Nonalcoholic Fatty Liver Disease |
| title_full | Peroxisome Proliferator-Activated Receptors Associated with Nonalcoholic Fatty Liver Disease |
| title_fullStr | Peroxisome Proliferator-Activated Receptors Associated with Nonalcoholic Fatty Liver Disease |
| title_full_unstemmed | Peroxisome Proliferator-Activated Receptors Associated with Nonalcoholic Fatty Liver Disease |
| title_short | Peroxisome Proliferator-Activated Receptors Associated with Nonalcoholic Fatty Liver Disease |
| title_sort | peroxisome proliferator activated receptors associated with nonalcoholic fatty liver disease |
| url | http://dx.doi.org/10.1155/2017/6561701 |
| work_keys_str_mv | AT nanwang peroxisomeproliferatoractivatedreceptorsassociatedwithnonalcoholicfattyliverdisease AT ruikong peroxisomeproliferatoractivatedreceptorsassociatedwithnonalcoholicfattyliverdisease AT huiluo peroxisomeproliferatoractivatedreceptorsassociatedwithnonalcoholicfattyliverdisease AT xiaorongxu peroxisomeproliferatoractivatedreceptorsassociatedwithnonalcoholicfattyliverdisease AT jielu peroxisomeproliferatoractivatedreceptorsassociatedwithnonalcoholicfattyliverdisease |